Notable from Our Podcast
The April 24, 2018, podcast featured interview highlighted the AAN Practice Guideline for disease-modifying therapies in multiple sclerosis. In the second segment, you'll hear an interview on the increasing global burden of neurologic disease.
Author Tip
A hybrid open access (OA) option is offered to authors whose full-length articles or reviews have been accepted for publication (not all manuscript categories are eligible for this option; please contact the editorial office for details). Authors submitting work to Neurology will be given the opportunity to select the OA option at the revision stage of the peer-review process, contingent upon acceptance of the paper. This choice has no influence on the peer review and acceptance processes. These articles are subject to the standard peer-review process and will be accepted or rejected based on their merit. The Article Processing Charge depends on the type of funding. For more information, please see neurology.org/open-access/neuro/faq.
From the AAN Press Room
Visit AAN.com/pressroom for the latest press releases
Does menopausal hormone therapy maintain the brain?
Taking menopausal hormone therapy soon after menopause to relieve symptoms may also benefit the brain. “We found that one form of menopausal hormone therapy taken soon after menopause may preserve brain structure in the portion of the brain responsible for memory and thinking skills,” said study author Kejal Kantarci, MD, MS, of the Mayo Clinic in Rochester, Minn., and a member of the American Academy of Neurology. “It may also reduce the development of amyloid plaques that can build up and lead to memory loss.”
Kantarci K, Tosakulwong N, Lesnick TG, et al. Neurology 2018;90:e1404–e1412. doi.org/10.1212/WNL.0000000000005325.
CME
Encephalitis with mGluR5 antibodies: Symptoms and antibody effects
Page 1002
Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis
Page 1006
Most-Read Articles
As of February 23, 2018
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
G. McKhann, D. Drachman, M. Folstein, et al. 1984;34:939–944. doi.org/10.1212/WNL.34.7.939.
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
J.F. Kurtzke. 1983;33:1444–1452. doi.org/10.1212/WNL.33.11.1444.
Parkinsonism: onset, progression, and mortality
M.M. Hoehn and M.D. Yahr. 1967;17:427–442. doi.org/10.1212/WNL.17.5.427.
Neurosurgical horizons in Parkinson's disease
C.G. Goetz, M.R. De Long, R.D. Penn, and R.A.E. Bakay. 1993;43:1–7. doi.org/10.1212/WNL.43.1_Part_1.1.
Autosomal dominant cerebellar phenotypes: The genotype has settled the issue
R.N. Rosenberg. 1995;45:1–5. doi.org/10.1212/WNL.45.1.1.
- © 2018 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
